Oncology
Sponsored
Oncology in the NHS: Situations, challenges, and solutions
Oncology is a singularly complex healthcare area. In clinical terms, …
19800 items found
News
Exscientia trims pipeline to focus on top cancer prospects
UK biotech Exscientia has tapped the brakes on the rapid expansion of …
Sales & Marketing
EU pharmaceutical reform: Balancing access, innovation, and concerns
After much anticipation, some leaks, and several delays, the European …
Digital
Digital therapeutics at a turning point: What we heard at DTx East
This year the digital therapeutics space took a hit with the downfall …
News
Takeda pulls Exkivity in US after failed confirmatory trial
Takeda has decided to withdraw its cancer drug Exkivity from the …
Patients
Finding a long-term fix to UK’s growing patient waiting list
The pandemic severely hindered the UK’s ability to treat patients in …
Patients
How the rise of medical device use in pharma R&D is driving wearable technology in healthcare and revolutionising the medical industry
As wearable technologies continue to rapidly develop, the use cases …
News
AZ pays $425m to settle claims heartburn drugs caused harm
AstraZeneca confirmed this morning it has agreed to pay $425 million …
News
FDA turns down Lilly’s eczema drug lebrikizumab
Problems at a contract manufacturing organisation have scuppered Eli …
News
WHO clears Oxford malaria jab for immunisation programmes
The World Health Organization (WHO) has recommended the use of a …
News
mRNA scientists share Nobel prize for medicine
Katalin Karikó and Drew Weissman of the University of Pennsylvania …
News
Novartis adds another string to iptacopan’s bow
Novartis has another phase 3 trial win in its quiver for targeted …
News
Wegovy romps ahead after key rival sees slowdown
Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago.
Digital
Sponsored
The AI effect in pharma commercial strategy: From data to re...
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Sales & Marketing
Sponsored
Seeking a single source of truth: Standardisation of the dat...
Oskar Mӧbert, Vice President of OpenData at Veeva Systems, spoke with Ian Cornish, Associate Director of Data Platforms at Astellas, about the company’s decision to opt into Veeva’s OpenDat
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
EHS&S for Biopharma & Pharma Summit
Implementing Corporate & Regulatory-Guided EHS Practices to Achieve Zero Biosafety, Ergonomic & Chemical Incidents for Employee Safety Across Global Facilities
R&D
Partner Content
Proteomic Based Drug Discovery Summit 2025
Determine Optimum Application of Proteomics to Accelerate Screening of Novel Targets, Unravel the Mode of Action, & Identify Biomarkers to Progress Small Molecule Drug Discovery & T
